Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

SML2783

Sigma-Aldrich

VU0409551

≥98% (HPLC)

Sinónimos:

JNJ 46778212, JNJ-46778212, VU 0409551, [6,7-Dihydro-2-(phenoxymethyl)oxazolo[5,4-c]pyridin-5(4H)-yl](4-fluorophenyl)methanone

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C20H17FN2O3
Número de CAS:
1363281-27-9
Peso molecular:
352.36
MDL number:
MFCD29047143
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(N1CCC2=C(C1)OC(COC3=CC=CC=C3)=N2)C4=CC=C(C=C4)F

Biochem/physiol Actions

VU0409551 (JNJ-46778212) is an orally available, potent and selective biased metabotropic glutamate receptor subtype 5 positive allosteric modulator (mGlu5 PAM). VU0409551 (JNJ-46778212) selectively potentiates mGlu5 coupling to Gaq-mediated signaling without modulation of NMDAR currents in hippocampal neurons. VU0409551 exhibits potent antipsychotic-like and cognition enhancing activity in animal models.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Shane D Hellyer et al.
Journal of neurochemistry, 151(3), 301-315 (2019-08-04)
Allosteric modulators of metabotropic glutamate receptor 5 (mGlu5 ) are a promising therapeutic strategy for a number of neurological disorders. Multiple mGlu5 -positive allosteric modulator (PAM) chemotypes have been discovered that act as either pure PAMs or as PAM-agonists in
Darrick T Balu et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 41(8), 2052-2061 (2016-01-08)
There is substantial evidence that NMDA receptor (NMDAR) hypofunction contributes to the pathophysiology of schizophrenia (SCZ). A recent large-scale genome-wide association study identified serine racemase (SR), the enzyme that produces the NMDAR co-agonist D-serine, as a risk gene for SCZ.
Jerri M Rook et al.
Neuron, 86(4), 1029-1040 (2015-05-06)
Schizophrenia is associated with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling. The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely associated signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathology

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico